

FINANCIAL DISCLOSURE REPORT FOR CALENDAR YEAR 2018

Report Required by the Ethics
in Government Act of 1978
(5 U.S.C. app. §§ 101-111)

1. Person Reporting (last name, first, middle initial) Ray, J. Thomas	2. Court or Organization U. S. District Court - ED AR	3. Date of Report 04/24/2019
4. Title (Article III judges indicate active or senior status; magistrate judges indicate full- or part-time) U. S. Magis. Judge - Full Time	5a. Report Type (check appropriate type) ☐ Nomination ☐ Date ☐ Initial ☒ Annual ☐ Final 5b. ☐ Amended Report	6. Reporting Period 01/01/2018 to 12/31/2018
7. Chambers or Office Address Richard Sheppard Arnold United States Courthouse 500 West Capitol, Room D 144 Little Rock, AR 72201		
IMPORTANT NOTES: The instructions accompanying this form must be followed. Complete all parts, checking the NONE box for each part where you have no reportable information.		

I. POSITIONS. (Reporting individual only; see pp. 9-13 of filing instructions.)

☐ NONE (No reportable positions.)

	<u>POSITION</u>	<u>NAME OF ORGANIZATION/ENTITY</u>
1.	Trustee	Rollover IRA
2.	Trustee	IRA #1
3.	Trustee	Inherited IRA
4.	Trustee	IRA # 2
5.		
6.		

II. AGREEMENTS. (Reporting individual only; see pp. 14-16 of filing instructions.)

☒ NONE (No reportable agreements.)

	<u>DATE</u>	<u>PARTIES AND TERMS</u>
1.		
2.		
3.		

FINANCIAL DISCLOSURE REPORT

Page 2 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

III. NON-INVESTMENT INCOME. *(Reporting individual and spouse; see pp. 17-24 of filing instructions.)***A. Filer's Non-Investment Income**NONE *(No reportable non-investment income.)*

DATE

SOURCE AND TYPE

INCOME

(yours, not spouse's)

1.

2.

3.

4.

B. Spouse's Non-Investment Income - *If you were married during any portion of the reporting year, complete this section.**(Dollar amount not required except for honoraria.)*NONE *(No reportable non-investment income.)*

DATE

SOURCE AND TYPE

1.

2.

3.

4.

IV. REIMBURSEMENTS *-- transportation, lodging, food, entertainment.**(Includes those to spouse and dependent children; see pp. 25-27 of filing instructions.)*NONE *(No reportable reimbursements.)*

SOURCE

DATES

LOCATION

PURPOSE

ITEMS PAID OR PROVIDED

1.

2.

3.

4.

5.

FINANCIAL DISCLOSURE REPORT

Page 3 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

V. GIFTS. *(Includes those to spouse and dependent children; see pp. 28-31 of filing instructions.)*

☒ NONE *(No reportable gifts.)*

SOURCE	DESCRIPTION	VALUE
1.		
2.		
3.		
4.		
5.		

VI. LIABILITIES. *(Includes those of spouse and dependent children; see pp. 32-33 of filing instructions.)*

☒ NONE *(No reportable liabilities.)*

CREDITOR	DESCRIPTION	VALUE CODE
1.		
2.		
3.		
4.		
5.		

FINANCIAL DISCLOSURE REPORT

Page 4 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
1. Abbvie C.S.	A	Dividend	K	T					
2. Acadia C.S.		None			Sold	03/01/18	K		
3. Agios C.S.		None	K	T					
4. Allergan C.S.	B	Dividend	L	T	Sold (part)	08/02/18	M		
5. Alphabet Inc (Cl A) C.S.		None	K	T	Buy	12/31/18	K		
6. Amazon C.S.		None	K	T	Buy	12/24/18	K		
7. Amgen	B	Dividend	L	T					
8. Anheuser Busch Inbev ADR	A	Dividend	L	T	Buy	10/10/18	M		
9. Bank of America C.S.	B	Dividend	L	T					
10. Berkshire Hathaway (B) C.S.		None	M	T					
11. Biomarin C.S.		None	K	T					
12. Bristol Meyers C.S.	A	Dividend	K	T					
13. Celgene C.S.		None	N	T					
14. Chevron C.S.	D	Dividend	M	T					
15. Conoco Phillips C.S.	C	Dividend	L	T	Sold (part)	01/29/18	L	E	
16. Eli Lilly C.S.	D	Dividend	N	T	Sold (part)	01/29/18	L	F	
17. Enterprise Products Partners L.P.	D	Dividend	L	T					

1. Income Gain Codes:	A = \$1,000 or less	B = \$1,001 - \$2,500	C = \$2,501 - \$5,000	D = \$5,001 - \$15,000	E = \$15,001 - \$50,000
(See Columns B1 and D4)	F = \$50,001 - \$100,000	G = \$100,001 - \$1,000,000	H1 = \$1,000,001 - \$5,000,000	H2 = More than \$5,000,000	
2. Value Codes	J = \$15,000 or less	K = \$15,001 - \$50,000	L = \$50,001 - \$100,000	M = \$100,001 - \$250,000	
(See Columns C1 and D3)	N = \$250,001 - \$500,000	O = \$500,001 - \$1,000,000	P1 = \$1,000,001 - \$5,000,000	P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes	P3 = \$25,000,001 - \$50,000,000		P4 = More than \$50,000,000		
(See Column C2)	Q = Appraisal	R = Cost (Real Estate Only)	S = Assessment	T = Cash Market	
	U = Book Value	V = Other	W = Estimated		

FINANCIAL DISCLOSURE REPORT

Page 5 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

18. Exxon Mobil Corp. C.S.	D	Dividend	M	T	Sold (part)	01/11/18	M	F	
19. Gilead, C.S.	D	Dividend	N	T	Sold (part)	01/26/18	L		
20. Incyte C.S.		None			Sold	11/05/18	K		
21. Intel C.S.	A	Dividend	K	T	Sold (part)	01/02/18	K	E	
22. J P Morgan Chase C.S.	B	Dividend	L	T					
23. Johnson & Johnson C.S.	D	Dividend	N	T					
24. Merck & Co. Inc. C.S.	D	Dividend	N	T					
25. Microsoft C.S.	A	Dividend	K	T	Buy	12/24/18	J		
26. Pfizer Inc. C.S.	C	Dividend	M	T					
27. Phillips 66 C.S.	A	Dividend	K	T	Sold (part)	05/16/18	M	F	
28. Phillips 66 Partners C.S.	A	Dividend	J	T	Sold (part)	05/16/18	L	D	
29. Regeneron Inc.		None	M	T	Sold (part)	08/22/18	M	C	
30. Sanofi Aventis C.S.	C	Dividend	L	T					
31. Valero Energy C.S.	C	Dividend	L	T	Sold (part)	01/02/18	L	F	
32. Wells Fargo C.S.	A	Dividend	K	T	Sold (part)	02/02/18	K	E	
33. Charles Schwab Money Market (Cash Equivalents)	C	Interest	L	T					
34.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 6 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "X" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

35. ORI/Acadia & Ver. Par., LA; McGowan Inc.; Zachry Exploration	F	Royalty	N	W					
36. ORI/Regan County, TX/Pioneer Natural Resources	A	Royalty	L	W					
37. W/I; Acadia & Vermillion Par., LA; McGowan Inc.	E	Royalty	N	W					
38. ORI/Acadia Par., LA; Zachry Exploraton	D	Royalty	N	W					
39. Investment Property (Pulaski County, AR) (See Section VIII)		None	N	W					
40.									
41. Rollover IRA									
42. - Charles Schwab Money Market (Cash Equivalents)	B	Interest	L	T					
43. - Acadia Pharmaceuticals C.S.		None			Sold	02/21/18	K	B	
44. - Agios C.S.		None	L	T					
45. Allergan C.S.	B	Dividend	L	T	Sold (part)	08/21/18	M		
46. Alphabet (Class A) C.S.		None	L	T	Buy	12/21/18	L		
47. Amazon C.S.		None	L	T	Buy	12/27/18	L		
48. Anheuser Busch Inbev ADR	A	Dividend	L	T	Buy	10/01/18	M		
49. Apple C.S.	A	Dividend	L	T	Buy	12/27/18	L		
50. Applied Materials C.S.	A	Dividend	K	T	Buy	12/20/18	K		
51. - Amgen C.S.	D	Dividend	M	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 7 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "X" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
52. - Bank of America C.S.	A	Dividend			Sold	11/14/18	K	E	
53. - Berkshire Hathaway (B) C.S.		None	M	T					
54. - Biogen C.S.		None	K	T	Buy	10/31/18	K		
55. - Celgene C.S.		None	M	T					
56. - Chevron C.S.	B	Dividend	L	T					
57. - Conoco Phillips C.S.	B	Dividend	L	T					
58. - CVS C.S.	A	Dividend	L	T	Buy	12/27/18	L		
59. - Energy Transfer L.P.	C	Dividend	K	T	Buy	12/17/18	L		
60. - Enterprise Products Partners L.P.	C	Dividend	L	T					
61. - Exxon C.S.	A	Dividend			Sold	01/16/18	L	E	
62. - Gilead Sciences Inc. C.S.	D	Dividend	M	T					
63. - Incyte C.S.		None	K	T					
64. - Intel C.S.	A	Dividend	K	T	Buy	10/24/18	K		
65. - J.P. Morgan C.S.	B	Dividend	K	T					
66. - Johnson & Johnson C.S.	B	Dividend	L	T	Sold (part)	12/17/18	L	F	
67. - Lumentum C.S.		None	K	T	Buy	12/27/18	K		
68. - Merck & Co. Inc. C.S.	A	Dividend	K	T	Sold (part)	11/26/18	K	E	

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 8 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
69. - Microsoft C.S.	A	Dividend	K	T	Buy	12/27/18	K		
70. - Pfizer Inc. C.S.	A	Dividend	K	T	Sold (part)	11/26/18	K	D	
71. - Phillips 66 C.S.	A	Dividend			Sold	11/26/18	L	E	
72. - Phillips 66 Partners L.P.	A	Dividend			Sold	10/09/18	K	D	
73. - Pioneer Natural Resources C.S.	A	Dividend	L	T	Buy	12/11/18	L		
74. - Regeneron C.S.		None	K	T	Sold (part)	08/22/18	M	D	
75. - Sanofi Aventis C.S.	B	Dividend			Sold	10/23/18	K	D	
76. - Stemline Therapeutics C.S.		None			Sold	10/23/18	K	D	
77. - Whiting Petroleum C.S.		None			Sold	10/23/18	J	A	
78.									
79. IRA #1									
80. - Abbvie C.S.	A	Dividend			Sold	01/16/18	J	C	
81. - Acadia Pharm. C.S.		None			Sold	03/26/18	J		
82. - Allergan C.S.	A	Dividend	K	T					
83. - Amgen Inc. C.S.	B	Dividend	K	T					
84. - Berkshire Hathaway (B) C.S.		None	L	T					
85. - Biomarin C.S.		None	J	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 9 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

86. - Celgene C.S.		None	L	T					
87. - Conoco C.S.	A	Dividend			Sold	01/16/18	J	B	
88. - Exxon Mobil C.S.	A	Dividend			Sold	01/16/18	J	C	
89. - Gilead Sciences Inc. C.S.	A	Dividend	K	T					
90. - Johnson & Johnson C.S.	A	Dividend	K	T					
91. - J.P. Morgan Chase C.S.	A	Dividend	J	T					
92. - Merck C.S.	A	Dividend	J	T	Sold (part)	11/12/18	J	D	
93. - Pfizer C.S.	A	Dividend	J	T	Sold (part)	11/12/18	J	D	
94. - Pioneer Natural Resources C.S.	A	Dividend	J	T	Buy	11/14/18	J		
95. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
96.									
97. Inherited IRA									
98. - AbbVie Inc. C.S.	A	Dividend			Sold	01/16/18	J	C	
99. - Acadia Pharm. C.S.		None			Sold	01/16/18	J	A	
100. - Agios C.S.		None	J	T					
101. - Allergan C.S.	A	Dividend	K	T					
102. - Berkshire Hathaway C.S.		None	K	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 10 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
103. - Celgene C.S.		None	K	T					
104. - Chevron C.S.	A	Dividend	J	T					
105. - Conoco Phillips C.S.	A	Dividend			Sold	01/16/18	J	B	
106. - Gilead Science Inc. C.S.	A	Dividend	K	T					
107. - Incyte C.S.		None	J	T	Buy	02/02/18	J		
108. - Johnson & Johnson C.S.	A	Dividend			Sold	12/07/18	J	B	
109. - Merck C.S.	A	Dividend	J	T					
110. - Pfizer C.S.	A	Dividend			Sold	01/16/18	J	A	
111. - Proctor & Gamble C.S.	A	Dividend			Sold	01/16/18	J	A	
112. - Regeneron C.S.		None	K	T	Buy	04/27/18	K		
113. - Wells Fargo & Co. C.S.	A	Dividend			Sold	01/16/18	J	B	
114. - Whiting Petroleum C.S.		None			Sold	01/03/18	J		
115. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
116.									
117.									
118. IRA #2									
119. - Allergan C.S.	A	Dividend	K	T					

1. Income Gain Codes: (See Columns B1 and D4)	A ~\$1,000 or less F ~\$50,001 - \$100,000	B ~\$1,001 - \$2,500 G ~\$100,001 - \$1,000,000	C ~\$2,501 - \$5,000 H1 ~\$1,000,001 - \$5,000,000	D ~\$5,001 - \$15,000 H2 ~More than \$5,000,000	E ~\$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J ~\$15,000 or less N ~\$250,001 - \$500,000 P3 ~\$25,000,001 - \$50,000,000	K ~\$15,001 - \$50,000 O ~\$500,001 - \$1,000,000	L ~\$50,001 - \$100,000 P1 ~\$1,000,001 - \$5,000,000 P4 ~More than \$50,000,000	M ~\$100,001 - \$250,000 P2 ~\$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 11 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
120. - Amgen Inc. C.S.	B	Dividend	K	T					
121. - Bank of America C.S.	A	Dividend			Sold	11/14/18	J	D	
122. - Berkshire Hathaway (B) C.S.		None	K	T					
123. - Celgene C.S.		None	L	T					
124. - Exxon C.S.	A	Dividend			Sold	01/16/18	J	C	
125. - Gilead Sciences Inc. C.S.	A	Dividend	K	T					
126. - Johnson & Johnson C.S.	A	Dividend	K	T					
127. - Merck C.S.	A	Dividend	K	T	Sold (part)	11/12/18	K	D	
128. - Microsoft C.S.	A	Dividend	J	T	Buy	12/24/18	J		
129. - Pfizer Inc. C.S.	A	Dividend	K	T	Sold (part)	11/12/18	J	D	
130. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
131.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 12 of 13

Name of Person Reporting	Date of Report
Ray, J. Thomas	04/24/2019

VIII. ADDITIONAL INFORMATION OR EXPLANATIONS. *(Indicate part of report.)*

Explanation 1:
On last year's Financial Disclosure Report (01/01/17 to 12/31/17), line 42 reflected rental income produced from a house located on a tract of investment property. Since filing that report, the house has been demolished.
Therefore, the investment property (without the house), which is now listed on line 39 of the current FDR, no longer produces any rental income.

FINANCIAL DISCLOSURE REPORT

Page 13 of 13

Name of Person Reporting

Ray, J. Thomas

Date of Report

04/24/2019

IX. CERTIFICATION.

I certify that all information given above (including information pertaining to my spouse and minor or dependent children, if any) is accurate, true, and complete to the best of my knowledge and belief, and that any information not reported was withheld because it met applicable statutory provisions permitting non-disclosure.

I further certify that earned income from outside employment and honoraria and the acceptance of gifts which have been reported are in compliance with the provisions of 5 U.S.C. app. § 501 et. seq., 5 U.S.C. § 7353, and Judicial Conference regulations.

Signature: s/ **J. Thomas Ray**

NOTE: ANY INDIVIDUAL WHO KNOWINGLY AND WILLFULLY FALSIFIES OR FAILS TO FILE THIS REPORT MAY BE SUBJECT TO CIVIL AND CRIMINAL SANCTIONS (5 U.S.C. app. § 104)

Committee on Financial Disclosure
Administrative Office of the United States Courts
Suite 2-301
One Columbus Circle, N.E.
Washington, D.C. 20544